

Review

Roles of Cancer Exosomes in Immunosuppression and Immune Evasion

Mona Sheta ^{1,2,†}, Eman A. Taha ^{3,†}, Yanyin Lu ^{1,4} and Takanori Eguchi ^{1,*}

¹ Department of Dental Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8525, Japan; p9mw1s0r@s.okayama-u.ac.jp (M.S.), riku21@s.okayama-u.ac.jp (Y.L.)

² Medical Biochemistry and Molecular Biology Unit, Department of Cancer Biology, National Cancer Institute, Cairo University, Cairo 11796, Egypt

³ Department of Biochemistry, Faculty of Science, Ain Shams University, Cairo 11566, Egypt; eman-taha8990@gmail.com (E.A.T.)

⁴ Department of Oral and Maxillofacial Surgery, Stomatological Center, Peking University Shenzhen Hospital, Shenzhen 518036, China

* Correspondence: eguchi@okayama-u.ac.jp; Tel.: +81 86 235 6661

Abstract: Extracellular vesicles (EV), including exosomes and microvesicles, are released from various cells and alter recipient cell phenotypes and fates by their biomolecules. Here we review current knowledge about tumor EVs and how they prompt malignant cell communication with tumor-associated cells, such as cancer-associated fibroblasts, tumor endothelial cells, and immune cells. We delineate the major pathways and molecular players that influence each step of cancer initiation, progression, and resistance. Of note, cancer exosomes involve immunosuppression by tumor-associated macrophages, myeloid-derived suppressor cells, and regulatory T cells. Moreover, tumor exosomes can induce the apoptosis of killer T cells and immune checkpoint of dendritic cells and attenuate natural killer cells. An in-depth understanding of EV biology is essential to ensure the clinical development of exosome/EV-based therapeutic products, which will be of benefit to exosome manipulation in cancer management.

Keywords: exosomes; extracellular vesicles; cellular communication; tumor microenvironment; tumor infiltrating lymphocyte; immunosuppression; immune evasion; therapy resistance

1. Introduction

Communication of cancer cells with neighboring and distant cells is crucial for tumor growth and progression. Extracellular vesicles (EVs) are lipid membrane-surrounded vesicles released from cells under physiological and pathological conditions. EVs contain a variety of molecular cargos such as proteins, long and small RNA, DNA, lipid, glycan, minerals, and metabolites [1–9]. Earlier studies classified EVs into exosomes (40–150 nm), microvesicles (100–500 nm), and apoptotic bodies (1–10 µm) based on their mechanisms of biosynthetic pathways and release, while additional types of EVs have been named based on the history of discovery or conceptually, such as oncosomes [10–12], large oncosomes (1–10 µm) [10], stressome, including damaged membrane vesicles [13], matrix vesicles [14], migrasomes [15], exopheres [16] (generated upon neurotoxic stress, ~4 µm), and exomeres (~35 nm) [17,18]. Recent studies have defined the EVs according to the size of vesicles, such as small EVs (sEV), medium EVs (mEV), and large EVs (L-EV). Further, exosomes have been recently classified based on their size: small exosomes (Exo-S) and large exosomes (Exo-L). EVs play trash bag-like roles as cells discard redundant disadvantageous factors, while EVs also mediate trans-cellular communications as their cargos stimulate and reprogram recipient cells through cell signalings or molecular transfer [6,19–22]. Thus, EVs and their cargos are essential for autocrine, paracrine, juxtacrine, and endocrine signals. EVs, including exosomes, are contained in bodily fluids that are sources of biomarkers, such as blood, saliva, cerebrospinal fluid, lymph fluid, sweat, tears, urine,

milk, and seminal fluid. Therefore, EVs can play key roles in cell-to-cell communication in local tissue and between distant organs, individuals, and species [23,24].

2. Exosomes biogenesis and composition

Endocytosis is a dynamic process by which cells internalize macromolecules and surface proteins. Exosomes are endosomal origin vesicles, which take part in paracrine interactions between the cells [25], initially formed as internal luminal vesicles (ILVs) in multivesicular bodies (MVBs) by ESCRT-dependent or ESCRT-independent mechanisms. First, the proteins are transported from the trans-Golgi network (TGN) (e.g., MHC class-II molecules) or internalized from the cellular surface (e.g., activated growth factor receptors). Second, these proteins are ubiquitylated at their cytosolic domains; however, not all proteins require ubiquitinylation to be targeted into the vesicles. After vesicle accumulation, the MVBs have several fates; (i) be directed to the lysosome for degradation (e.g., EGF), (ii) be recycled to the TGN, (iii) or be fused with the plasma membrane resulting in the release of the ILVs known as exosomes [26].

Exosome membranes are enriched in lipids, such as cholesterol, sphingomyelin, and ceramide. The EV contents vary greatly depending on the originating cell. Classical exosome markers, such as tetraspanins (TSPANs; CD9, CD63, CD81, and CD82), heat shock proteins (HSPs), Rabs, Alix, and Annexins, are often lost from exosomes in some pathological conditions but found in other EV types, such as large EVs [3,9,27–30]. DNA and RNAs, including mRNAs, microRNAs, and long noncoding RNAs (lncRNA), are also present in the exosome and other EV types and are crucial players in EV biology [3,8,9,31–36]. Exosomes are internalized by other cells through direct membrane fusion, endocytosis, or cell-type-specific phagocytosis. Exosomes released by tumor cells frequently include oncoproteins linked to different cancer types. The list of proteins found in exosomes is continuously expanding on ExoCarta, a database of exosomal proteins, RNA, and lipids [37] (Table 1).

EV production often correlates with tumor cell transformation, such as epithelial-to-mesenchymal transition (EMT) [13,38–41] and cancer stemness [42,43]. Moreover, recent studies suggest that the EMT progression is correlated with higher PD-L1 expression, immunosuppression, and immune evasion by M2 macrophages, myeloid-derived suppressor cells (MDSC), and regulatory T cells (Treg), whereas the epithelial tumors with lower PD-L1 expression, less Treg and MDSC are susceptible to immune attack by M1 macrophages and killer T cells [44].

Table 1. Top 10 proteins identified in exosomes as indicated in the ExoCarta database.

Gene name	Protein name	Number of times identified
CD9	CD9, tetraspanin 29	98
HSPA8	HSC70, Heat shock cognate 71 kDa protein	97
PDCD6IP	Programmed cell death 6-interacting protein	96
GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	95
ACTB	Actin Beta	93
ANXA2	Annexin A2	83
CD63	LAMP-3, CD63, tetraspanin 30	82
SDCBP	Syndecan Binding Protein	78
ENO1	Enolase 1	78
HSP90AA1	HSP90α, Heat Shock Protein 90 Alpha Family Class A Member 1	77

3. Cancer exosomes transfer oncogenic factors to tumor-associated cells

EVs could cause cellular reprogramming and genetic alterations by transferring their cargo contents, such as oncoproteins, lipids, mRNAs, and noncoding RNAs, defined as “oncosomes.” Increasing evidence elucidated that tumor cells release exosomes to repro-

gram normal and stromal cells in the tumor microenvironment to provoke tumor initiation, progression, metastasis, and drug resistance. For great examples, mutant KRAS [45] and mutant EGFR [24,45] were found in exosomes and transferred to recipient cells leading to cancer progression [12,46]. Tumor oncosomal MMP3 is transferred to recipient cells and alters transcriptional programs, such as cellular communication network factor 2 (CCN2) expression, in the tumor microenvironment [47,48].

4. Tumor exosomes develop the resistant microenvironment

Individual residence cells in the tumor microenvironment (TME), each with different biological contributions, interact dynamically to create a unique microenvironment for neoplastic cells. One method of communication between the tumor-associated cells (TACs) delivers exosomes to each other in the TME, which induces phenotypic modifications and remodeling of TACs, causing cancer propagation. Several studies have proved the involvement of cancer exosomes in the modulation of ³⁹. Along with mediating cell-to-cell communication, tumor exosomes develop cancer therapy resistance [49] (Fig. 1).




Figure 1. Cancer cells secrete various exosomes/EVs with different cargo, which plays pivotal roles in shaping the tumor-associated cells. Cancer exosomes induce normal fibroblast cells into CAF (A) and polarization of macrophages into M2-type macrophages with an immunosuppressive phenotype (B), ultimately favoring tumor progression and chemoresistance. Cancer exosomes and M2 macrophage-derived exosomes (C) alter the T cell phenotype to immunosuppressive Treg cells, which suppress the maturation of DCs and killer T cells.

4.1. Exosomes mediate Tumor-CAF communication to develop chemoresistance

Fibroblasts are major components of tumor stroma, while recent studies evoked the existence of cancer-associated fibroblasts (CAFs). CAFs include myofibroblasts and are differentiated from mesenchymal stem cells (MSCs). Myofibroblasts are a major component of the tumor stroma and mediate angiogenesis, which can be modulated by the cancer exosomes [50,51]. It is worth noting that tumor stroma rich in myofibroblastic cells can maintain tumor growth, vascularization, and metastasis. Webber et al. demonstrated that exosomal TGF- β promotes the differentiation of fibroblasts into myofibroblasts through

the SMAD signaling pathway [26,52]. Cho et al. suggested that breast cancer-derived exosomes stimulate the differentiation of MSCs in adipose tissue into a myofibroblast-like phenotype with a significant increase in α -SMA and other protumorigenic factors, such as VEGF, SDF-1, TGF- β , and CCL5 [53]. Chowdhury et al. proposed that prostate cancer-derived exosomes provoke the MSC differentiation into myofibroblastic cells with an increase in VEGF-A, resulting in proangiogenic functions [54]. Moreover, EGFR-positive tumor-derived exosomes promote angiogenesis by reprogramming the tumor endothelial cells (TECs) into VEGF-secretion phenotype [46]. These studies indicated that tumor exosomes play key roles in augmenting CAFs, myofibroblasts, MSCs, and TECs. CAF-derived exosomal microRNA (miRNA, miR) signature supports the communication between tumor cells and other stromal residents in the TME, which promotes cancer progression and therapeutic resistance [55–57]. In esophageal cancer, cisplatin resistance was correlated to exosomal miR-27a/b and its target TGF- β [58]. miR-522 overexpression in CAFs was correlated with cisplatin/paclitaxel resistance of gastric tumor through activation of ubiquitin-specific protease 7 (USP7) / hnRNPA1 axis, inhibiting arachidonate lipoxygenase 15 (ALOX15) and ultimately decreased chemosensitivity [59]. Exosome-enriched miR-196a is transferred from CAF to adjacent tumor cells inducing platinum resistance [60]. Additionally, miR-164a and SNAI1 are delivered directly from CAF to pancreatic cancer cells via exosomes, leading to gemcitabine (GEM) resistance of tumor cells. The resistance can be reversed by treatment with GW4869, an inhibitor of exosome release [61,62]. miR-106b from CAFs was also transferred to cancer cells, which conferred GEM by targeting TP53INP1 (Tumor protein p53 inducible nuclear protein 1) [63]. Besides, miR-21 was reported in GEM-induced chemoresistance [64]. Further, miR-21-rich exosomes released from cancer-associated adipocytes significantly reduced tumor cells' sensitivity to paclitaxel by targeting apoptotic protease activating factor-1 (APAF1) in the ovarian neoplasm microenvironment [65]. Besides, exosome-enriched lncRNA H19 was transferred from CAFs to adjacent colorectal cells, activating the Wnt/ β -catenin signaling pathway and inducing chemoresistance [66,67] (Fig. 1).

4.2. Cancer stem cell-derived exosomes arrange the tumor microenvironment toward tumor progression and immunosuppression

Stem cells were first found in hematopoietic cells and thus designated hematopoietic stem cells (HSCs) [68]. Unequivocal proof of HSCs has given way to the prospective isolation of tissue-specific stem and progenitor cells [69]. Tumors may often originate from the transformation of normal stem cells, and cancer cells may include sub-populations with stem cell phenotypes called cancer stem cells (CSCs), cancer-initiating cells (CICs), or tumor-initiating cells (TICs). Paradoxically, teratoma formation in experimental animals is one of the features of induced pluripotent stem (iPS) cells [70]. Indeed, an increase in the expression of pluripotent stem cell (PSC) markers has been found in CSCs [42,71–73]. Currently defined characteristics of CSCs are cellular aggregation, spheroid formation, tumor initiation, slow cell cycle, entrance into dormancy, chemoresistance, SC marker expression, and pluripotency [42,43,74–76]. Dormant cancer cells within subclones can survive chemotherapy while proliferating subclones are relatively more chemosensitive [73]. Thus, tumors can relapse due to cells surviving after treatment and re-established subclonal diversity [74]. The parental tumors are a source of molecular cargos exported in exosomes and carry various CSC-specific proteins. For instance, in many malignancies, the Wnt/ β -catenin pathway is a key regulator of the CSC phenotype [77,78]. Several studies postulated the possibility of Wnt activation in surrounding tumor cells via absorption of β -catenin-rich exosomes [79,80]. Sheta et al. have postulated the significant role of FGF2 / FGFR signaling in favoring the transformation of normal stem cells into CSCs [81]. Besides, FGF2 in exosomes was proven to regulate stromal function [82,83], suggesting that the exosome released from the surrounding TME may lead to the development of CSCs. Similarly, various CSC-specific molecules are secreted with exosomes [84,85], which include (i) surface receptors (CD133, CD44, CD326/EpCAM), (ii) functional

enzymes (ALDH, MMPs), and (iii) pluripotency/stem cells factors (Oct4), which facilitate communication between cancer cells and the TME [38,48,76,86,87]. The dependency of such stromal cells highlights the involvement of miR-155-rich exosomes in reprogramming normal adjacent fibroblasts into CAFs [88]. Uptake of miR-155 by fibroblasts may account for the dramatic repression of Tumor Protein P53 Inducible Nuclear Protein 1 (TP53INP1) in pancreatic stromal cells. Further, gastric cancer-derived exosomes usually carry TGF- β [89] that activates the Smad pathway conducive to generating functional CAFs [89]. Further, CSCs-derived exosomes can induce immunosuppression. EGFR⁺ and HER2⁺ exosomes are often released from CSCs [90,91]. These receptors can stimulate the monocyte MAPK signaling pathway, which promotes the development of TAMs [92,93]. CSCs-derived exosomes have been found as carriers of miRNAs associated with ECM remodeling. miRNA-105, found in exosomes from breast cancer stem cells, directly alters endothelial tight junctions and raises the permeability of tumor blood arteries by targeting endothelial tight junction protein ZO-1 [94]. Besides, tumor endothelial cells (TECs) movement and the creation of early vascular lumens are induced by the interaction between the miR-92a found in exosomes produced by K562 tumor cells and the proangiogenic protein integrin- α 5 [95]. From here, CSC-exosomes are engaged in regulating the tumor microenvironment (Fig. 2).




Figure 2. Potential roles of CSCs-derived exosomes/EVs in tumors. HER2 and EGFR are abundant in CSC-exosomes and activate the MAPK signaling pathway in monocytes, which in turn induce the development of TAMs and promote immunosuppression. Exosomes rich in TGF β and miR-155 promote the production of CAFs, which aid in the development of the TME. Exosomes containing miR-105 reduce ZO-1 expression in TECs, increasing tumor blood vascular permeability in the TME. Additionally, exosomes that carry miR-92a interact with the proangiogenic protein integrin- α 5 to promote the migration of TECs and the early formation of vascular lumens, thereby encouraging angiogenesis.

4.3. Tumor exosomes induce endothelial cells angiogenesis, extravasation, and intravasation

Tumor endothelial cells (TECs) line tumor-associated blood vessels and assuring the passage of nutrients into tumor tissues [96]. TECs are abnormal in morphology, function, and gene expression [97]. TECs support tumor cells disseminating to the distal sites via extravasation and preserve them from anoikis, thereby promoting tumor metastasis [98]. TECs can also release angiocrine factors, such as VEGF, to support tumor progression [99,100]. Abnormal characteristics of TECs are caused by the tumor microenvironment, such as hypoxia that promotes the production of VEGF and increases vascular permeability and genetic instability in TECs [101]. While TECs adhere to the endothelia of venules, they will enter circulation, exit the bloodstream, position themselves upon distance endothelium surfaces, and subsequent metastatic growth [102,103]. Phosphatidylserine, the inner bilayer of the intact cellular membrane, and P-selectin glycoprotein ligand-1 (PSGL1) are considered to work together, promoting the exosome to adhere to the endothelium [103]. The phenotypic alterations of TECs were led by EVs that contain growth factors and receptors, such as VEGF and its receptor VEGFR1 [104,105], SDF1 / CXCL12 [106,107], FGF-4 [108], EGF [109], adrenomedullin [110], and TSP-1 [111]. CXCR4, a receptor for SDF1, is overexpressed in TECs, while a CXCR4 antagonist (plerixafor, also known as AMD3100) induced tumor angiogenic inhibition-triggered necrosis (TAITN) in head and neck squamous cell carcinoma (HNSC) [106]. TAITN reduced TECs that supplies oxygen to tumor cells, whereby the loss of TECs induced hypoxia [106]. Thus, chemokine signaling plays a key role in tumor angiogenesis, a novel therapeutic target. Tumor-derived exosomes are related to tumor growth and metastasis of HNSC and induce angiogenesis by reprogramming TECs [107]. Exosomal WNT4 from colorectal cancer stimulated β -catenin nuclear translocation in endothelial cells, which improved tumor growth and angiogenesis [112,113]. On the other hand, human liver stem cells (HLSC) derived EVs inhibited tumor angiogenesis since the HLSC-EVs possessed specific microRNAs, which targeted and downregulated proangiogenic genes. LncRNAs contained in exosomes can promote tumor angiogenesis. Exosomes released by CD90⁺ liver cancer cells promoted angiogenesis and adhesion of endothelial cells by providing lncRNA H19 [114]. LncRNA H19 also promoted angiogenesis in glioblastoma [115]. Exosomes derived from lung cancer cells contained the lncRNA growth arrest-specific 5 (lncRNA GAS5), up-regulating PTEN expression and inhibiting the PI3K/AKT phosphorylation, thereby increasing angiogenesis [116]. These studies indicate that tumor exosomes stimulate TECs to promote angiogenesis and metastasis.

4.4. Tumor-macrophage communication via exosomes for acquiring immunosuppression and chemoresistance

Macrophages are generally divided into the pro-inflammatory M1-type and immunosuppressive M2-type. M1-polarized macrophages possess antitumor activity, whereas M2-polarized macrophages promote tumor growth [117]. Tumor-associated macrophages (TAMs) are often M2-like phenotypes and are considered key participants in cancer progression via the production of numerous growth factors, cytokines, and extracellular matrix (ECM) remodeling molecules for stimulating cancer growth, migration, and angiogenesis [118]. Indeed, tongue cancer EVs stimulate macrophage polarity into M2-type, while HSP90 partially mediates the TAM polarization in HNSC [38]. Breast cancer-derived exosomal glycoprotein 130 (gp130) activates the IL-6 / STAT3 pathway in macrophages [119], consequently increasing macrophage survival and inducing the expression of several genes associated with tumorigenesis, such as IL-10, CXCR4, and CCL2 [119,120]. Each cytokine has a specific role in regulating tumor immune surveillance. IL-10 induces immunosuppressive effects by modulating dendritic cells and cytotoxic T cells [121], while CXCR4 is associated with proangiogenic and immunosuppressive phenotypes [120]. IL-6 and CCL2 (also called MCP-1: monocyte chemoattractant protein 1) are associated with TAM polarization [122]. These immunosuppressive effects are inhibited by adding a GP130 inhibitor to the cancer-derived exosomes [117]. Zheng et al. showed

that macrophage-derived exosomal miR-21 enhanced the PI3K/Akt signaling pathway, inhibited apoptosis by downregulating PTEN, and induced resistance to cisplatin in gastric cancer cells [123]. Likewise, Binenbaum et al. demonstrated that miR-365 transferred by M2 macrophage-derived exosomes increased the tri-phospho-nucleotide pool in pancreatic cancer cells and activated cytidine deaminase, which eventually conferred GEM resistance and supported tumor cells proliferation [124] (Fig. 1).

4.5. Cancer exosomes induce immunosuppressive Tregs and apoptosis of killer T cells

It has been suggested that tumor-infiltrating lymphocytes (TILs) include tumor-reactive lymphocytes and tumor antigen-specific lymphocytes. A therapy in which tumor-reactive T cells in TILs are expanded, cultured, and infused is being attempted. At the same time, it is suggested that many cells negatively regulate the antitumor immune response, such as regulatory T cells (Tregs), in TILs. Killer T cells, also called cytotoxic T lymphocytes (CTLs), are a group of CD3⁺ CD8⁺ T cells that exhibit cytotoxicity specifically to cells presenting antigen peptides on MHC class I molecules on the target cell surface. Killer T cells recognize antigen peptides and secrete cytotoxic granules that contain perforin and granzymes. Perforin polymerizes on the target cell membrane to form pores, and granzymes, which belong to serine proteases, invade the target cells through the pores and induce apoptosis of the target cells. Activated killer T cells are considered the master regulator of the antitumor immune response. A growing body of studies has reported the significance of CD4⁺ helper T cells in the generation and maintenance of effective cytotoxic and memory CD8⁺ T cells, known as CD4⁺ T-cell help. This phenomenon optimizes the expansion, trafficking, and effector function of CD8⁺ T cells, thereby potentiating immune-mediated tumor destruction [125–127]. Cancer cell-derived exosomes suppress these T cells, which are more sensitive to the suppressive effects of tumor exosomes than other immune cells. These immunosuppressive effects of cancer exosomes involve the induction of apoptosis, inhibition of proliferation and differentiation, and dysfunctionality of T cells. Yang et al. demonstrated that exosomes from ovalbumin peptide (OVA)-expressing melanoma suppressed OVA-specific immune response [128]. Several studies showed tumor exosomes induce T cell apoptosis through FasL, TNF, and galectin-9, located on the EV surface [129–132]. Furthermore, PTEN of tumor exosomes appeared to regulate the PI3K/AKT pathway, leading to AKT dephosphorylation and increasing the expression of pro-apoptotic BAX and decreasing anti-apoptotic Bcl-2, Bcl-xL, and MCL-1 (myeloid leukemia cell differentiation protein) in activated killer T cells [133–135]. Additionally, administration of GL26 glioblastoma exosomes to mice was associated with a reduction in the number of killer T cells and a decline in the IFN- γ and granzyme expression [136]. Clayton et al. reported that extracellular ectonucleotidases CD39 and CD73 contribute to rising adenosine levels in the tumor microenvironment by dephosphorylating exogenous ATP and 5'AMP to form adenosine and hence attenuating the T cell function [137]. Regulatory T cells (Tregs) are an immunosuppressive subset of CD4⁺ T cells and negatively impact the immune response. TGF- β 1 and IL-10 in exosomes stimulate the differentiation of CD4⁺ CD25⁻ T cells into Tregs and foster the Tregs proliferation by increasing the phosphorylated SMAD2/3 and STAT3 [138]. These studies demonstrated that cancer exosomes suppress killer T cells through activating pro-apoptotic signals and promoting differentiation of T cells into Tregs, immunosuppressive T cells (Fig. 2).

4.6. Tumor exosomes potentiate immunosuppressive roles of MDSCs

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells unable to differentiate into dendritic cells (DCs), macrophages, or granulocytes. MDSCs are one of the main drivers of immunosuppression in the tumor microenvironment, as they exhibit a strong suppressive capacity against T cells and NK cells antitumor activity, recruiting immunosuppressive Tregs and creating a microenvironment favorable for immunosuppression and tumor progression. Therefore, an increased

MDSCs frequency and activity were positively correlated with tumor progression and recurrence and negatively correlated with the immunotherapy efficacy and clinical outcomes [139]. Xiang et al. reported that tumor exosomes stimulated MDSC differentiation through TGF- β and prostaglandin E2 (PGE2) in vivo. Tumor exosomes also induce the expression of Cox2, IL-6, VEGF, and arginase-1 in the accumulating MDSCs. Blocking the tumor exosomal PGE2 and TGF- β activities disrupted the stimulatory effect of these exosomes on MDSC and attenuated MDSC-mediated immunosuppression [140]. It was recently shown that a chemokine CCL bound to cancer exosomes determines uptake by CXCR-expressing cells [141], and resident stroma-secreted chemokine CCL2 recruits MDSCs in the tumor microenvironment [142]. These findings suggested that tumor exosomes potentiate the immunosuppressive roles of MDSCs in regulating NK cells and T cells, whereas blocking immunosuppressive cytokines on the tumor exosomes attenuates the unfavorable immunosuppression by MDSCs.

4.7. Tumor exosomes downregulate a killing factor on natural killer cells

Natural Killer (NK) cells have abilities to kill tumor cells and virus-infected cells without prior sensitization. NK group 2 member D (NKG2D) protein is a type-II transmembrane receptor expressed on NK cells and killer T cells. In NK cells, NKG2D mediates the direct killing of target cells, whereas, in CD8⁺ killer T cells, it acts as a costimulatory receptor leading to activation of the T-cell receptor (TCR) and T-cell effector function [143,144]. Lundholm et al. found that exosomes from human prostate cancer express ligands for NKG2D on their surface, which selectively decreases the expression of the receptor NKG2D on NK and CD8⁺ killer T cells in a dose-dependent manner, leading to impairing the cytotoxic function of these killer cells and promoting the tumor immune escape [143]. Clayton et al. demonstrated that human prostate cancer cell exosomes (derived from PC-3 and DU-145 cell lines) express NKG2D ligands on their surface that downregulated NKG2D expression in effector lymphocytes [145]. Exosomal TGF- β might be involved in NKG2D downregulation because cell activity and NKG2D expression were restored by using TGF- β neutralizing antibody [146]. These studies indicated that NKG2D on the surface of NK cells is crucial for killing tumor cells, whereas tumor exosomes often express NKG2D-ligand that downregulates NKG2D on NK cells.

4.8. Tumor exosomes involve the immune checkpoint by stimulating dendritic cells to express PD-L1

Dendritic cells (DCs) are professional antigen-presenting cells (APCs) derived from bone marrow and play a central role in initiating the immune response. Upon capturing the antigens with their recognition receptors, DCs undergo maturation and travel to lymph nodes, where DCs present the captured antigens to naïve T cells for their activation and polarization, establishing links between innate and adaptive responses [147–149]. A recent study indicated that exosomes from Lewis lung carcinoma (LLC) cells inhibited the DCs maturation and cytokine production, suppressed the differentiation of bone marrow precursors into CD11c⁺ DCs, and induced apoptosis in DCs [150]. The LLC-derived exosomes up-regulated PD-L1 expression on DCs; thus, PD-L1 blockade immune checkpoint inhibitors (ICI) such as Nivolumab (marketed as Opdivo) significantly reversed the immunosuppressive effect of LLC exosomes on DCs. Moreover, Yang et al. showed that treating the DCs with tumor exosomes induced TGF- β production in DCs [128]. Thus, tumor exosomes involve the immune checkpoint by stimulating dendritic cells to express PD-L1.

5. Exosomal oncoproteins and oncolipid that enhance tumor progression and metastasis

The tumor microenvironment comprises a diverse range of cells, such as endothelial cells, fibroblasts, and immune cells. Direct interaction between tumor cells and their environment is necessary for cancer progression by enhancing angiogenesis, metastasis, and

suppressing tumor immunity [102]. Growing evidence indicates that cancer cell-derived exosomes transfer oncogenic proteins and nucleic acids that modulate the activity of recipient cells and promote tumor initiation, invasion, and metastasis. Matrix / moonlighting metalloproteinases (MMPs), especially MMP3 and MMP9, are protumorigenic cargos of EVs in cancer [151]. Notably, MMP3 in colon cancer EVs plays key roles in tumorigenesis and metastasis [47,48,76]. MMP3 in exosomes are transferred into recipient cell nuclei and trans-activate protumorigenic genes, such as cellular communication network factor 2 (CCN2) and HSPs [48,152–154]. A part of small EV subpopulations, exomeres, contains beta-galactoside α 2, 6-sialyltransferase 1 (ST6Gal-I), and amphiregulin (AREG) [155]. ST6Gal-I is transported from exomeres to recipient cells, triggering metastasis [156,157]. Besides, exosomes enriched in HSPs can play cytoprotective and anti-apoptotic roles in tumors and tumor-associated cells [13,151,158]. Metastatic tongue cancer exosomes abundantly contained members of the HSP family, such as TRAP1, HSP90 α , HSP90 β , HSP105, and HSP70s [27]. Besides, HSP90 α is released in EV-free forms upon hypoxia and can promote tumorigenesis [87]. Cell division control 37 (CDC37) is an intracellular cochaperone of HSP90 and plays protumorigenic roles in cancer [27,128,159]. The triple targeting of CDC37, HSP90 α , and HSP90 β inhibited protumorigenic exosomes in tongue and prostate cancer [38]. Nevertheless, extracellular HSPs can play immunogenic and immunosuppressive roles depending on the immune cells and their receptors that detect HSPs [160,161]. Redundant lipids are released from cells through the release of exosomes and cholesterol efflux pump proteins. One of such pumps overexpressed in metastatic cancer cells was adenosine triphosphate (ATP)-binding cassette G1 (ABCG1), which co-overexpressed with ABCG2, a drug efflux pump found in CSCs [43]. The targeted silencing of ABCG1 led to exosome lipid accumulation and triggered tumor cell death. These facts suggest that cancer cells can often release redundant toxic lipids, whereas loss of the ABCG1 pump could trigger the accumulation of redundant toxic lipids leading to tumor cell death. Macrophages play key roles in cholesterol transport from peripheral blood vessels to the liver. Therefore, TAMs may play key roles in metabolizing redundant and toxic lipids released by tumor cells.

6. Prognostic biomarkers in exosomes

Given the presence of special contents in exosomes reflecting the unique qualities and condition of the cells or tissues from whence they originated, there is a great interest in identifying exosome contents using transcriptomics and proteomics techniques [162–165]. Consequently, exosomes can be evaluated as potential sources of cancer diagnostic markers. For instance, Ahadi and co-workers profiled the lncRNAs content of exosomes derived from five different prostate cancer cell lines and identified a list of statistically significant expressed lncRNAs enriched within prostate cancer exosomes [166,167]. By comparing the proteomic contents of metastatic versus non-metastatic breast cancer, Vardaki et al. identified periostin as a candidate marker of localized disease or lymph node metastasis [167]. Metastatic tongue cancer cells-derived EVs abundantly contained members of HSPs such as TRAP1, HSP90 α , HSP90 β , HSP105, and HSP70s compared to less metastatic parental cells [27]. Further, Proteoglycan glypican-1 (GP1)-localized to exosome membranes was a possible marker for patients with pancreatic disease [168]. Also, miRNAs enriched in exosomes serve as tumor markers. For a great instance, in patients who experienced ovarian cancer, eight microRNA types (miR-21, miR-141, miR-200a, miR-200b, miR-200c, miR-203, miR-205, and miR-214)-positive exosomes were significantly distinct from profiles observed in healthy control patients, suggesting an effective way to screening asymptomatic ovarian cancer patients [169]. The effectiveness of exosomes as biomarkers depends on the enrichment of the markers within the exosome that would otherwise make up a very small amount of the secretome [170]. Salivary exosomes enriched with miR-1246 and miR-464 were investigated as candidate biomarkers for pancreaticobiliary tract cancer [171]. Along the same line, circulating exosomes from glioblastoma patients showed unique signatures of EGFRvIII mRNA, which can serve the role of

a “liquid-biopsy (such as blood collection)” rather than a “surgical tissue-biopsy” for glioblastoma detection [2]. This evidence implies that exosomes produced from bodily fluids could be a very informative and least noninvasive cancer detection tool. However, there are still challenges with using exosomes as biomarkers. For instance, (a) The heterogeneity / diversity of exosome population in biofluids is the first issue¹⁷². Different protein / RNA expression patterns and profiles may result from heterogeneous exosomes, leading to false negatives or positive errors in prognosis and diagnosis. (b) The second problem is the lack of a universal, verified biomarker for all malignancies, leading to co-isolation and impurity of harvested exosomes. (c) The third challenge is the difficulty of isolating and purifying exosomes [172,173]. Therefore, there was a huge disparity across clinical studies for identifying tumor-derived exosome biomarkers, and more research is required to evaluate the viability of using exosomes to diagnose cancer.

7. Therapeutic application of exosomes as delivery systems

As demonstrated by an expanding body of investigations, exosomes possess special characteristics, which make them ideal for delivering anticancer agents over conventional drug delivery vectors like liposomes, e.g., in vivo circulatory stability, high efficiency [174,175] and actively cross biological barriers [176]. Therefore, researchers have tried two strategies of loading exosomes with therapeutic compounds [177]: a direct loading of selective agents on the lumen or surface of exosomes and another indirect loading technique that uses co-culture with therapeutic agents to load agents into exosomes via the endosomal pathway or plasma membrane shedding, or genetic manipulation of the cells to express active molecules on their exosomes. Exosomal protein composition and lipid content might affect their propensity to target particular organs [178]. For instance, different types of integrins can modify the pharmacokinetics of exosomes and enhance their organ-tropic accumulation in the brain, lungs, or liver [179]. In addition, it was shown that pancreatic cells preferentially ingested exosomes harboring tetraspanin-8 in association with integrin- $\alpha 4$ [180]. EV lipids can also influence how well they are absorbed, e.g., phosphatidylserine has been linked to the absorption of EVs by macrophages [181]. In clinical trials for the tissue-specific delivery of biotherapeutics, exosomes are a potential delivery vector. Despite advantages, it has been shown that some obstacles are related to the drug delivery efficiency of exosomes [182–184], such as the lack of standards for isolation and purification and difficulty in preservation. Additionally, producer cell engineering methods for cargo loading might further customize exosomes for targeted distribution, which presents some challenges in terms of selecting dependable and secure source cells with a high level of exosomes production potential as well as selecting an efficient and cautious administration method for delivering exosomes into the site of tumor cells.

8. Conclusion

We presented evidence for EVs / exosomes involving cancer progression, metastasis, and therapy resistance. Of note, tumor exosomes involve immunosuppression and immune evasion by acting on M2 macrophages, MDSC, and Tregs. Moreover, cancer exosomes induce the apoptosis of killer T cells and immune checkpoint of dendritic cells and attenuate NK cells. EVs from tumors include a diverse range of biomolecules that influence local and distant tissue function, establishing cancer pathology via exosome cargo. Besides, due to their nanoscale size and non-proliferative nature, EVs are safe and practical for the development of new therapies. While more research is needed to develop logistical clinical diagnostics and therapeutics, exosomes appear to be important mediators, carrying promising biomarkers, and potential medicinal agents in cancer management.

Author Contributions: T.E. conceived the concept. M.S., E.A.T. and T.E. wrote the manuscript. M.S., Y.L. and T.E. draw figures. T.E. edited and revised the manuscript.

Funding: M.S. was supported by Japan Society for the Promotion of Science (JSPS) International Research Fellowship in Japan. T.E. was supported by JSPS Kakenhi Grants 22F22409-TE, 22H03511-

HO, 21H03119-TY, 21K08902-HY, 20H03888-HN, 20K20611-MT, 20K09904-CS, and 19H03817-MT, Wesco Scientific Promotion Foundation, and Okayama University.

Acknowledgments: The authors thank Hotaka Kawai and Yosuke Togashi for meaningful discussion. We generated figures using BioRender.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations:

αSMA	α-smooth muscle actin
CCL	C-C motif chemokine ligand
CTL	Cytotoxic T lymphocytes
CXCR	Chemokine receptor
DC	Dendritic cell
ECM	Extracellular matrix
EGFR	Epidermal growth factor receptor
ESCRT	Endosomal sorting complexes required for transport
EV	Extracellular vesicle
HLSC	Human liver stem cells
HNSC	Head and neck squamous cell carcinoma
IFN	Interferon
IL	Interleukin;
ILV	Internal luminal vesicle
lncRNA	Long noncoding RNA
MCL-1	Myeloid cell leukemia-1
MHC class-II	Molecules major histocompatibility complex class-II
MMP	Matrix / moonlighting metalloproteinase
MV	Microvesicle
MVB	Multivesicular body
OVA	Ovalbumin peptide
PI3K	Phosphatidylinositol 3-kinase
PKB/Akt	Protein kinase B
PTEN	Phosphatase and tensin homolog
SDF-1	Stromal cell-derived factor 1
STAT	Signal transducer and activator of transcription
TAC	Tumor-associated cell
TAITN	Tumor angiogenic inhibition triggered necrosis
TAM	Tumor-associated macrophage
TEC	Tumor endothelial cell
TIL	Tumor infiltrating lymphocytes
TGF-β	Transforming growth factor-beta
TME	Tumor microenvironment
TNF	Tumor necrosis factor
VEGF	Vascular endothelial growth factor

References

1. 1. Braicu, C.; Tomuleasa, C.; Monroig, P.; Cucuianu, A.; Berindan-Neagoe, I.; Calin, G. A. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? *Cell Death Differ* **2015**, *22*, 34–45.

2. 2. Skog, J.; Würdinger, T.; van Rijn, S.; Meijer, D. H.; Gainche, L.; Curry, W. T.; Carter, B. S.; Krichevsky, A. M.; Breakefield, X. O. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol* **2008**, *10*, 1470–1476.

3. 3. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J. J.; Lötvall, J. O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* **2007**, *9*.

4. 4. Colombo, M.; Raposo, G.; Théry, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. *Annu Rev Cell Dev Biol* **2014**, *30*.

5. 5. Fujita, Y.; Yoshioka, Y.; Ochiya, T. Extracellular vesicle transfer of cancer pathogenic components. *Cancer Sci* **2016**, *107*.

6. Pan, B. T.; Teng, K.; Wu, C.; Adam, M.; Johnstone, R. M. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. *Journal of Cell Biology* **1985**, 101.
7. Chiba, M.; Kimura, M.; Asari, S. Exosomes secreted from human colorectal cancer cell lines contain mRNAs, microRNAs and natural antisense RNAs, that can transfer into the human hepatoma HepG2 and lung cancer A549 cell lines. *Oncol Rep* **2012**, 28.
8. Kalluri, R.; Lebleu, V. S. Discovery of Double-Stranded Genomic DNA in Circulating Exosomes. *Cold Spring Harb Symp Quant Biol* **2016**, 81, 275–280.
9. Mathivanan, S.; Fahner, C. J.; Reid, G. E.; Simpson, R. J. ExoCarta 2012: Database of exosomal proteins, RNA and lipids. *Nucleic Acids Res* **2012**, 40.
10. Minciacchi, V. R.; Spinelli, C.; Reis-Sobreiro, M.; Cavallini, L.; You, S.; Zandian, M.; Li, X.; Mishra, R.; Chiarugi, P.; Adam, R. M.; et al. MYC mediates large oncosome-induced fibroblast reprogramming in prostate cancer. *Cancer Res* **2017**, 77.
11. Rak, J.; Guha, A. Extracellular vesicles - vehicles that spread cancer genes. *BioEssays* **2012**, 34.
12. Al-Nedawi, K.; Meehan, B.; Micallef, J.; Lhotak, V.; May, L.; Guha, A.; Rak, J. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. *Nat Cell Biol* **2008**, 10.
13. Eguchi, T.; Sogawa, C.; Ono, K.; Matsumoto, M.; Tran, M. T.; Okusha, Y.; Lang, B. J.; Okamoto, K.; Calderwood, S. K. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells. *Cells* **2020**, 9.
14. Shapiro, I. M.; Landis, W. J.; Risbud, M. v. Matrix vesicles: Are they anchored exosomes? *Bone* **2015**, 79.
15. Ma, L.; Li, Y.; Peng, J.; Wu, D.; Zhao, X.; Cui, Y.; Chen, L.; Yan, X.; Du, Y.; Yu, L. Discovery of the migrasome, an organelle mediating release of cytoplasmic contents during cell migration. *Cell Res* **2015**, 25.
16. Melentijevic, I.; Toth, M. L.; Arnold, M. L.; Guasp, R. J.; Harinath, G.; Nguyen, K. C.; Taub, D.; Parker, J. A.; Neri, C.; Gabel, C. v.; et al. C. elegans neurons jettison protein aggregates and mitochondria under neurotoxic stress. *Nature* **2017**, 542.
17. Zhang, H.; Freitas, D.; Kim, H. S.; Fabijanic, K.; Li, Z.; Chen, H.; Mark, M. T.; Molina, H.; Martin, A. B.; Bojmar, L.; et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. *Nat Cell Biol* **2018**, 20.
18. van Niel, G.; D'Angelo, G.; Raposo, G. Shedding light on the cell biology of extracellular vesicles. *Nat Rev Mol Cell Biol* **2018**, 19.
19. Heijnen, H. F. G.; Schiel, A. E.; Fijnheer, R.; Geuze, H. J.; Sixma, J. J. Activated platelets release two types of membrane vesicles: Microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and α -granules. *Blood* **1999**, 94.
20. Huggins, C.; Scott, W. W.; Heinen, J. H. CHEMICAL COMPOSITION OF HUMAN SEMEN AND OF THE SECRETIONS OF THE PROSTATE AND SEMINAL VESICLES. *American Journal of Physiology-Legacy Content* **1942**, 136.
21. McAndrews, K. M.; Kalluri, R. Mechanisms associated with biogenesis of exosomes in cancer. *Mol Cancer* **2019**, 18.
22. Zhao, H.; Achreja, A.; Iessi, E.; Logozzi, M.; Mizzoni, D.; di Raimo, R.; Nagrath, D.; Fais, S. The key role of extracellular vesicles in the metastatic process. *Biochim Biophys Acta Rev Cancer* **2018**, 1869.
23. Zhang, M.; Viennois, E.; Xu, C.; Merlin, D. Plant derived edible nanoparticles as a new therapeutic approach against diseases. *Tissue Barriers* **2016**, 4.
24. Mu, J.; Zhuang, X.; Wang, Q.; Jiang, H.; Deng, Z. bin; Wang, B.; Zhang, L.; Kakar, S.; Jun, Y.; Miller, D.; et al. Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. *Mol Nutr Food Res* **2014**, 58.
25. Amini, H.; Rezabakhsh, A.; Heidarzadeh, M.; Hassanpour, M.; Hashemzadeh, S.; Ghaderi, S.; Sokullu, E.; Rahbarghazi, R.; Reiter, R. J. An Examination of the Putative Role of Melatonin in Exosome Biogenesis. *Front Cell Dev Biol* **2021**, 9.
26. Webber, J. P.; Spary, L. K.; Sanders, A. J.; Chowdhury, R.; Jiang, W. G.; Steadman, R.; Wymant, J.; Jones, A. T.; Kynaston, H.; Mason, M. D.; et al. Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. *Oncogene* **2015**, 34.
27. Ono, K.; Eguchi, T.; Sogawa, C.; Calderwood, S. K.; Futagawa, J.; Kasai, T.; Seno, M.; Okamoto, K.; Sasaki, A.; Kozaki, K. ichi HSP-enriched properties of extracellular vesicles involve survival of metastatic oral cancer cells. *J Cell Biochem* **2018**, 119, 7350–7362.
28. Mears, R.; Craven, R. A.; Hanrahan, S.; Totty, N.; Upton, C.; Young, S. L.; Patel, P.; Selby, P. J.; Banks, R. E. Proteomic analysis of melanoma-derived exosomes by two-dimensional polyacrylamide gel electrophoresis and mass spectrometry. *Proteomics* **2004**, 4.
29. Gastpar, R.; Gehrmann, M.; Bausero, M. A.; Asea, A.; Gross, C.; Schroeder, J. A.; Multhoff, G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. *Cancer Res* **2005**, 65.
30. Mathivanan, S.; Ji, H.; Simpson, R. J. Exosomes: Extracellular organelles important in intercellular communication. *J Proteomics* **2010**, 73.
31. Park, J. E.; Dutta, B.; Tse, S. W.; Gupta, N.; Tan, C. F.; Low, J. K.; Yeoh, K. W.; Kon, O. L.; Tam, J. P.; Sze, S. K. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. *Oncogene* **2019**, 38.
32. Li, J.; Tian, T.; Zhou, X. The role of exosomal shuttle RNA (esRNA) in lymphoma. *Crit Rev Oncol Hematol* **2019**, 137.

33. 33. Li, S.; Li, Y.; Chen, B.; Zhao, J.; Yu, S.; Tang, Y.; Zheng, Q.; Li, Y.; Wang, P.; He, X.; et al. ExoRBase: A database of circRNA, lncRNA and mRNA in human blood exosomes. *Nucleic Acids Res* **2018**, *46*.
34. 34. Hessvik, N. P.; Sandvig, K.; Llorente, A. Exosomal miRNAs as biomarkers for prostate cancer. *Front Genet* **2013**, *4*.
35. 35. Boon, R. A.; Vickers, K. C. Intercellular transport of MicroRNAs. *Arterioscler Thromb Vasc Biol* **2013**, *33*.
36. 36. Yang, M.; Chen, J.; Su, F.; Yu, B.; Su, F.; Lin, L.; Liu, Y.; Huang, J. D.; Song, E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. *Mol Cancer* **2011**, *10*.
37. 37. Mathivanan, S.; Fahner, C. J.; Reid, G. E.; Simpson, R. J. ExoCarta 2012: database of exosomal proteins, RNA and lipids. *Nucleic Acids Res* **2012**, *40*, D1241–D1244.
38. 38. Ono, K.; Sogawa, C.; Kawai, H.; Tran, M. T.; Taha, E. A.; Lu, Y.; Oo, M. W.; Okusha, Y.; Okamura, H.; Ibaragi, S.; et al. Triple knockdown of CDC37, HSP90- α and HSP90- β diminishes extracellular vesicles-driven malignancy events and macrophage M2 polarization in oral cancer. *J Extracell Vesicles* **2020**, *9*.
39. 39. Eguchi, T.; Sheta, M.; Fujii, M.; Calderwood, S. K. Cancer extracellular vesicles, tumoroid models, and tumor microenvironment. *Semin Cancer Biol* **2022**.
40. 40. Fujiwara, T.; Eguchi, T.; Sogawa, C.; Ono, K.; Murakami, J.; Ibaragi, S.; Asaumi, J. ichi; Okamoto, K.; Calderwood, S. K.; Kozaki, K. ichi Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition. *Biochem Biophys Res Commun* **2018**, *503*, 1267–1272.
41. 41. Fujiwara, T.; Eguchi, T.; Sogawa, C.; Ono, K.; Murakami, J.; Ibaragi, S.; Asaumi, J. ichi; Calderwood, S. K.; Okamoto, K.; Kozaki, K. ichi Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab. *Oral Oncol* **2018**, *86*, 251–257.
42. 42. Eguchi, T.; Sogawa, C.; Okusha, Y.; Uchibe, K.; Inuma, R.; Ono, K.; Nakano, K.; Murakami, J.; Itoh, M.; Arai, K.; et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. *PLoS One* **2018**, *13*.
43. 43. Namba, Y.; Sogawa, C.; Okusha, Y.; Kawai, H.; Itagaki, M.; Ono, K.; Murakami, J.; Aoyama, E.; Ohyama, K.; Asaumi, J. I.; et al. Depletion of lipid efflux pump ABCG1 triggers the intracellular accumulation of extracellular vesicles and reduces aggregation and tumorigenesis of metastatic cancer cells. *Front Oncol* **2018**, *8*.
44. 44. Jiang, Y.; Zhan, H. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. *Cancer Lett* **2020**, *468*, 72–81.
45. 45. Beckler, M. D.; Higginbotham, J. N.; Franklin, J. L.; Ham, A. J.; Halvey, P. J.; Imasuen, I. E.; Whitwell, C.; Li, M.; Liebler, D. C.; Coffey, R. J. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. *Molecular and Cellular Proteomics* **2013**, *12*.
46. 46. Al-Nedawi, K.; Meehan, B.; Kerbel, R. S.; Allison, A. C.; Rak, J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. *Proc Natl Acad Sci U S A* **2009**, *106*, 3794.
47. 47. Okusha, Y.; Eguchi, T.; Sogawa, C.; Okui, T.; Nakano, K.; Okamoto, K.; Kozaki, K. I. The intranuclear PEX domain of MMP involves proliferation, migration, and metastasis of aggressive adenocarcinoma cells. *J Cell Biochem* **2018**, *119*.
48. 48. Okusha, Y.; Eguchi, T.; Tran, M. T.; Sogawa, C.; Yoshida, K.; Itagaki, M.; Taha, E. A.; Ono, K.; Aoyama, E.; Okamura, H.; et al. Extracellular Vesicles Enriched with Moonlighting Metalloproteinase Are Highly Transmissive, Pro-Tumorigenic, and Trans-Activates Cellular Communication Network Factor (CCN2/CTGF): CRISPR against Cancer. *Cancers (Basel)* **2020**, *12*.
49. 49. Kugeratski, F. G.; Kalluri, R. Exosomes as mediators of immune regulation and immunotherapy in cancer. *FEBS J* **2021**, *288*, 10–35.
50. 50. Merjane, M.; Langlois, A.; Larochelle, S.; Cloutier, C. B.; Ricard-Blum, S.; Moulin, V. J. Pro-angiogenic capacities of microvesicles produced by skin wound myofibroblasts. *Angiogenesis* **2017**, *20*.
51. 51. Han, K. Y.; Tran, J. A.; Chang, J. H.; Azar, D. T.; Zieske, J. D. Potential role of corneal epithelial cell-derived exosomes in corneal wound healing and neovascularization. *Sci Rep* **2017**, *7*.
52. 52. Webber, J.; Steadman, R.; Mason, M. D.; Tabi, Z.; Clayton, A. Cancer exosomes trigger fibroblast to myofibroblast differentiation. *Cancer Res* **2010**, *70*.
53. 53. Cho, J. A.; Park, H.; Lim, E. H.; Kim, K. H.; Choi, J. S.; Lee, J. H.; Shin, J. W.; Lee, K. W. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. *Gynecol Oncol* **2011**, *123*.
54. 54. Chowdhury, R.; Webber, J. P.; Gurney, M.; Mason, M. D.; Tabi, Z.; Clayton, A. Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. *Oncotarget* **2015**, *6*, 715.
55. 55. Guo, Q. R.; Wang, H.; Yan, Y. da; Liu, Y.; Su, C. Y.; Chen, H. B.; Yan, Y. Y.; Adhikari, R.; Wu, Q.; Zhang, J. Y. The Role of Exosomal microRNA in Cancer Drug Resistance. *Front Oncol* **2020**, *10*.
56. 56. Zhong, Y.; Li, H.; Li, P.; Chen, Y.; Zhang, M.; Yuan, Z.; Zhang, Y.; Xu, Z.; Luo, G.; Fang, Y.; et al. Exosomes: A New Pathway for Cancer Drug Resistance. *Front Oncol* **2021**, *11*, 3846.
57. 57. Li, J.; Gao, N.; Gao, Z.; Liu, W.; Pang, B.; Dong, X.; Li, Y.; Fan, T. The Emerging Role of Exosomes in Cancer Chemo-resistance. *Front Cell Dev Biol* **2021**, *9*, 2985.
58. 58. Tanaka, K.; Miyata, H.; Sugimura, K.; Fukuda, S.; Kanemura, T.; Yamashita, K.; Miyazaki, Y.; Takahashi, T.; Kurokawa, Y.; Yamasaki, M.; et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts. *Carcinogenesis* **2015**, *36*, 894–903.

59. Zhang, H.; Deng, T.; Liu, R.; Ning, T.; Yang, H.; Liu, D.; Zhang, Q.; Lin, D.; Ge, S.; Bai, M.; et al. CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer. *Mol Cancer* **2020**, *19*.
60. Qin, X.; Guo, H.; Wang, X.; Zhu, X.; Yan, M.; Wang, X.; Xu, Q.; Shi, J.; Lu, E.; Chen, W.; et al. Exosomal miR-196a derived from cancer-associated fibroblasts confers cisplatin resistance in head and neck cancer through targeting CDKN1B and ING5. *Genome Biol* **2019**, *20*.
61. Richards, K. E.; Zeleniak, A. E.; Fishel, M. L.; Wu, J.; Littlepage, L. E.; Hill, R. Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells. *Oncogene* **2017**, *36*, 1770–1778.
62. You, J.; Li, M.; Cao, L. M.; Gu, Q. H.; Deng, P. B.; Tan, Y.; Hu, C. P. Snail1-dependent cancer-associated fibroblasts induce epithelial-mesenchymal transition in lung cancer cells via exosomes. *QJM* **2019**, *112*, 581–590.
63. Fang, Y.; Zhou, W.; Rong, Y.; Kuang, T.; Xu, X.; Wu, W.; Wang, D.; Lou, W. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. *Exp Cell Res* **2019**, 383.
64. Zhang, L.; Yao, J.; Li, W.; Zhang, C. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. *Oncol Res* **2018**, *26*, 827–836.
65. Au Yeung, C. L.; Co, N. N.; Tsuruga, T.; Yeung, T. L.; Kwan, S. Y.; Leung, C. S.; Li, Y.; Lu, E. S.; Kwan, K.; Wong, K. K.; et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. *Nat Commun* **2016**, *7*.
66. Ren, J.; Ding, L.; Zhang, D.; Shi, G.; Xu, Q.; Shen, S.; Wang, Y.; Wang, T.; Hou, Y. Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19. *Theranostics* **2018**, *8*, 3932–3948.
67. Deng, X.; Ruan, H.; Zhang, X.; Xu, X.; Zhu, Y.; Peng, H.; Zhang, X.; Kong, F.; Guan, M. Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. *Int J Cancer* **2020**, *146*, 1700–1716.
68. Reya, T.; Morrison, S. J.; Clarke, M. F.; Weissman, I. L. Stem cells, cancer, and cancer stem cells. *Nature* **2001**, *414*, 105–111.
69. Hara, E. S.; Ono, M.; Eguchi, T.; Kubota, S.; Pham, H. T.; Sonoyama, W.; Tajima, S.; Takigawa, M.; Stuart, K. C.; Kuboki, T. miRNA-720 controls stem cell phenotype, proliferation and differentiation of human dental pulp cells. *PLoS One* **2013**, *8*.
70. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **2006**, *126*, 663–676.
71. Raj, D.; Aicher, A.; Heeschen, C. Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation. *Stem Cells* **2015**, *33*.
72. Jeter, C. R.; Yang, T.; Wang, J.; Chao, H. P.; Tang, D. G. Concise Review: NANOG in Cancer Stem Cells and Tumor Development: An Update and Outstanding Questions. *Stem Cells* **2015**, *33*, 2381–2390.
73. Sogawa, C.; Eguchi, T.; Namba, Y.; Okusha, Y.; Aoyama, E.; Ohyama, K.; Okamoto, K. Gel-Free 3D Tumoroids with Stem Cell Properties Modeling Drug Resistance to Cisplatin and Imatinib in Metastatic Colorectal Cancer. *Cells* **2021**, *Vol. 10*, Page 344 **2021**, *10*, 344.
74. Kreso, A.; Dick, J. E. Evolution of the cancer stem cell model. *Cell Stem Cell* **2014**, *14*, 275–291.
75. Malanchi, I.; Santamaria-Martínez, A.; Susanto, E.; Peng, H.; Lehr, H. A.; Delaloye, J. F.; Huelsken, J. Interactions between cancer stem cells and their niche govern metastatic colonization. *Nature* **2012**, 481.
76. Taha, E. A.; Sogawa, C.; Okusha, Y.; Kawai, H.; Oo, M. W.; Elseoudi, A.; Lu, Y.; Nagatsuka, H.; Kubota, S.; Satoh, A.; et al. Knockout of MMP3 Weakens Solid Tumor Organoids and Cancer Extracellular Vesicles. *Cancers* **2020**, *Vol. 12*, Page 1260 **2020**, *12*, 1260.
77. de Sousa e Melo, F.; Vermeulen, L. Wnt Signaling in Cancer Stem Cell Biology. *Cancers (Basel)* **2016**, *8*.
78. Ben-Ze'ev, A.; Basu, S.; Haase, G. Wnt signaling in cancer stem cells and colon cancer metastasis. *F1000Res* **2016**, *5*.
79. Chairoungdua, A.; Smith, D. L.; Pochard, P.; Hull, M.; Caplan, M. J. Exosome release of β -catenin: a novel mechanism that antagonizes Wnt signaling. *J Cell Biol* **2010**, *190*, 1079–1091.
80. Gross, J. C.; Chaudhary, V.; Bartscherer, K.; Boutros, M. Active Wnt proteins are secreted on exosomes. *Nat Cell Biol* **2012**, *14*, 1036–1045.
81. Sheta, M.; Hassan, G.; Afify, S. M.; Monzur, S.; Kumon, K.; Abu Quora, H. A.; Farahat, M.; Zahra, M. H.; Fu, X.; Seno, A.; et al. Chronic exposure to FGF2 converts iPSCs into cancer stem cells with an enhanced integrin/focal adhesion/PI3K/AKT axis. *Cancer Lett* **2021**, *521*, 142–154.
82. Marrow Stromal Cells Secrete FGF2 in Exosomes, Providing Paracrine Protection for Leukemia Cells from Kinase Inhibitors. *Blood* **2017**, *130*, 306.
83. Javid-Sharifi, N.; Martinez, J.; English, I.; Joshi, S. K.; Scopim-Ribiero, R.; Edwards, V. D. K.; Agarwal, A.; Lopez, C.; Jorgens, D.; Tyner, J. W.; et al. FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells. *Elife* **2019**, *8*.
84. Nakamura, K.; Sawada, K.; Kinose, Y.; Yoshimura, A.; Toda, A.; Nakatsuka, E.; Hashimoto, K.; Mabuchi, S.; Morishige, K. I.; Kurachi, H.; et al. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. *Mol Cancer Res* **2017**, *15*, 78–92.

85. 85. Sharghi-Namini, S.; Tan, E.; Ong, L. L. S.; Ge, R.; Asada, H. H. Dll4-containing exosomes induce capillary sprout retraction in a 3D microenvironment. *Sci Rep* **2014**, *4*.
86. 86. Zhou, Y.; Zhang, Y.; Gong, H.; Luo, S.; Cui, Y. The Role of Exosomes and Their Applications in Cancer. *International Journal of Molecular Sciences* **2021**, Vol. 22, Page 12204 **2021**, *22*, 12204.
87. 87. Eguchi, T.; Sogawa, C.; Okusha, Y.; Uchibe, K.; Inuma, R.; Ono, K.; Nakano, K.; Murakami, J.; Itoh, M.; Arai, K.; et al. Organoids with cancer stem cell-like properties secrete exosomes and HSP90 in a 3D nanoenvironment. *PLoS One* **2018**, *13*.
88. 88. Pang, W.; Su, J.; Wang, Y.; Feng, H.; Dai, X.; Yuan, Y.; Chen, X.; Yao, W. Pancreatic cancer-secreted miR-155 implicates in the conversion from normal fibroblasts to cancer-associated fibroblasts. *Cancer Sci* **2015**, *106*, 1362.
89. 89. Gu, J.; Qian, H.; Shen, L.; Zhang, X.; Zhu, W.; Huang, L.; Yan, Y.; Mao, F.; Zhao, C.; Shi, Y.; et al. Gastric Cancer Exosomes Trigger Differentiation of Umbilical Cord Derived Mesenchymal Stem Cells to Carcinoma-Associated Fibroblasts through TGF- β /Smad Pathway. *PLoS One* **2012**, *7*.
90. 90. Lee, K. S.; Choi, J. S.; Cho, Y. W. Reprogramming of cancer stem cells into non-tumorigenic cells using stem cell exosomes for cancer therapy. *Biochem Biophys Res Commun* **2019**, *512*, 511–516.
91. 91. Li, X.; Li, X.; Zhang, B.; He, B. The Role of Cancer Stem Cell-Derived Exosomes in Cancer Progression. *Stem Cells Int* **2022**, *2022*.
92. 92. Raggi, C.; Mousa, H. S.; Correnti, M.; Sica, A.; Invernizzi, P. Cancer stem cells and tumor-associated macrophages: a roadmap for multitargeting strategies. *Oncogene* **2016** *35*:6 **2015**, *35*, 671–682.
93. 93. Xu, B.; Huo, Z.; Huang, H.; Ji, W.; Bian, Z.; Jiao, J.; Sun, J.; Shao, J. The expression and prognostic value of the epidermal growth factor receptor family in glioma. *BMC Cancer* **2021**, *21*, 1–14.
94. 94. Zhou, W.; Fong, M. Y.; Min, Y.; Somlo, G.; Liu, L.; Palomares, M. R.; Yu, Y.; Chow, A.; O'Connor, S. T. F.; Chin, A. R.; et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. *Cancer Cell* **2014**, *25*, 501.
95. 95. Umezu, T.; Ohyashiki, K.; Kuroda, M.; Ohyashiki, J. H. Leukemia cell to endothelial cell communication via exosomal miRNAs. *Oncogene* **2013**, *32*, 2747–2755.
96. 96. Dudley, A. C. Tumor endothelial cells. *Cold Spring Harb Perspect Med* **2012**, *2*.
97. 97. Baluk, P.; Hashizume, H.; McDonald, D. M. Cellular abnormalities of blood vessels as targets in cancer. *Curr Opin Genet Dev* **2005**, *15*.
98. 98. Yadav, A.; Kumar, B.; Yu, J. G.; Old, M.; Teknos, T. N.; Kumar, P. Tumor-associated endothelial cells promote tumor metastasis by chaperoning circulating tumor cells and protecting them from anoikis. *PLoS One* **2015**, *10*.
99. 99. Butler, J. M.; Kobayashi, H.; Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. *Nat Rev Cancer* **2010**, *10*.
100. 100. Maishi, N.; Hida, K. Tumor endothelial cells accelerate tumor metastasis. *Cancer Sci* **2017**, *108*.
101. 101. Taylor, S. M.; Nevis, K. R.; Park, H. L.; Rogers, G. C.; Rogers, S. L.; Cook, J. G.; Bautch, V. L. Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. *Blood* **2010**, *116*.
102. 102. van Zijl, F.; Krupitza, G.; Mikulits, W. Initial steps of metastasis: cell invasion and endothelial transmigration. *Mutat Res* **2011**, *728*, 23–34.
103. 103. Bern, M. M. Extracellular vesicles: how they interact with endothelium, potentially contributing to metastatic cancer cell implants. *Clin Transl Med* **2017**, *6*, 33.
104. 104. Matsuda, K.; Ohga, N.; Hida, Y.; Muraki, C.; Tsuchiya, K.; Kurosu, T.; Akino, T.; Shih, S. C.; Totsuka, Y.; Klagsbrun, M.; et al. Isolated tumor endothelial cells maintain specific character during long-term culture. *Biochem Biophys Res Commun* **2010**, *394*.
105. 105. Adya, R.; Tan, B. K.; Pun, A.; Chen, J.; Randeva, H. S. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. *Cardiovasc Res* **2008**, *78*, 356–365.
106. 106. Yoshida, S.; Kawai, H.; Eguchi, T.; Sukegawa, S.; Oo, M. W.; Anqi, C.; Takabatake, K.; Nakano, K.; Okamoto, K.; Nagatsuka, H. Tumor angiogenic inhibition triggered necrosis (Taitn) in oral cancer. *Cells* **2019**, *8*.
107. 107. Ludwig, N.; Yerneni, S. S.; Razzo, B. M.; Whiteside, T. L. Exosomes from HNSCC Promote Angiogenesis through Reprogramming of Endothelial Cells. *Mol Cancer Res* **2018**, *16*, 1798–1808.
108. 108. Cao, Z.; Ding, B. sen; Guo, P.; Lee, S. B.; Butler, J. M.; Casey, S. C.; Simons, M.; Tam, W.; Felsher, D. W.; Shido, K.; et al. Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance. *Cancer Cell* **2014**, *25*.
109. 109. Amin, D. N.; Hida, K.; Bielenberg, D. R.; Klagsbrun, M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. *Cancer Res* **2006**, *66*.
110. 110. Tsuchiya, K.; Hida, K.; Hida, Y.; Muraki, C.; Ohga, N.; Akino, T.; Kondo, T.; Miseki, T.; Nakagawa, K.; Shindoh, M.; et al. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. *Int J Oncol* **2010**, *36*.
111. 111. Bussolati, B.; Assenzio, B.; Deregibus, M. C.; Camussi, G. The proangiogenic phenotype of human tumor-derived endothelial cells depends on thrombospondin-1 downregulation via phosphatidylinositol 3-kinase/Akt pathway. *J Mol Med* **2006**, *84*.

112. Huang, Z.; Feng, Y. Exosomes derived from hypoxic colorectal cancer cells promote angiogenesis through Wnt4-Induced β -catenin signaling in endothelial cells. *Oncol Res* **2017**, *25*.
113. Lopatina, T.; Grange, C.; Fonsato, V.; Tapparo, M.; Brossa, A.; Fallo, S.; Pitino, A.; Herrera-Sanchez, M. B.; Kholia, S.; Camussi, G.; et al. Extracellular vesicles from human liver stem cells inhibit tumor angiogenesis. *Int J Cancer* **2019**, *144*.
114. Conigliaro, A.; Costa, V.; lo Dico, A.; Saieva, L.; Buccheri, S.; Dieli, F.; Manno, M.; Raccosta, S.; Mancone, C.; Tripodi, M.; et al. CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. *Mol Cancer* **2015**, *14*.
115. Jiang, X.; Yan, Y.; Hu, M.; Chen, X.; Wang, Y.; Dai, Y.; Wu, D.; Wang, Y.; Zhuang, Z.; Xia, H. Increased level of H19 long noncoding RNA promotes invasion, angiogenesis, and stemness of glioblastoma cells. *J Neurosurg* **2016**, *124*.
116. Cheng, Y.; Dai, X.; Yang, T.; Zhang, N.; Liu, Z.; Jiang, Y. Low Long Noncoding RNA Growth Arrest-Specific Transcript 5 Expression in the Exosomes of Lung Cancer Cells Promotes Tumor Angiogenesis. *J Oncol* **2019**, *2019*.
117. Ham, S.; Lima, L. G.; Chai, E. P. Z.; Muller, A.; Lobb, R. J.; Krumeich, S.; Wen, S. W.; Wiegmanns, A. P.; Möller, A. Breast cancer-derived exosomes alter macrophage polarization via gp130/STAT3 signaling. *Front Immunol* **2018**, *9*.
118. Yu, H.; Pardoll, D.; Jove, R. STATs in cancer inflammation and immunity: A leading role for STAT3. *Nat Rev Cancer* **2009**, *9*.
119. Bromberg, J.; Wang, T. C. Inflammation and Cancer: IL-6 and STAT3 Complete the Link. *Cancer Cell* **2009**, *15*.
120. Beider, K.; Bitner, H.; Leiba, M.; Gutwein, O.; Koren-Michowitz, M.; Ostrovsky, O.; Abraham, M.; Wald, H.; Galun, E.; Peled, A.; et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. *Oncotarget* **2014**, *5*.
121. Ruffell, B.; Chang-Strachan, D.; Chan, V.; Rosenbusch, A.; Ho, C. M. T.; Pryer, N.; Daniel, D.; Hwang, E. S.; Rugo, H. S.; Coussens, L. M. Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. *Cancer Cell* **2014**, *26*.
122. Roca, H.; Varcos, Z. S.; Sud, S.; Craig, M. J.; Pienta, K. J. CCL2 and interleukin-6 promote survival of human CD11b+ peripheral blood mononuclear cells and induce M2-type macrophage polarization. *Journal of Biological Chemistry* **2009**, *284*.
123. Zheng, P.; Chen, L.; Yuan, X.; Luo, Q.; Liu, Y.; Xie, G.; Ma, Y.; Shen, L. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. *J Exp Clin Cancer Res* **2017**, *36*.
124. Binenbaum, Y.; Fridman, E.; Yaari, Z.; Milman, N.; Schroeder, A.; David, G. ben; Shlomi, T.; Gil, Z. Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma. *Cancer Res* **2018**, *78*, 5287–5299.
125. Borst, J.; Ahrends, T.; Bąbala, N.; Melief, C. J. M.; Kastenmüller, W. CD4+ T cell help in cancer immunology and immunotherapy. *Nat Rev Immunol* **2018**, *18*.
126. Bedoui, S.; Heath, W. R.; Mueller, S. N. CD4+ T-cell help amplifies innate signals for primary CD8+ T-cell immunity. *Immunol Rev* **2016**, *272*.
127. Zhang, S.; Zhang, H.; Zhao, J. The role of CD4 T cell help for CD8 CTL activation. *Biochem Biophys Res Commun* **2009**, *384*.
128. Yang, C.; Kim, S. H.; Bianco, N. R.; Robbins, P. D. Tumor-derived exosomes confer antigen-specific immunosuppression in a murine delayed-type hypersensitivity model. *PLoS One* **2011**, *6*.
129. Andreola, G.; Rivoltini, L.; Castelli, C.; Huber, V.; Perego, P.; Deho, P.; Squarcina, P.; Accornero, P.; Lozupone, F.; Lugini, L.; et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. *Journal of Experimental Medicine* **2002**, *195*.
130. Taylor, D. D.; Gerçel-Taylor, Ç.; Lyons, K. S.; Stanson, J.; Whiteside, T. L. T-Cell Apoptosis and Suppression of T-Cell Receptor/CD3- ζ by Fas Ligand-Containing Membrane Vesicles Shed from Ovarian Tumors. *Clinical Cancer Research* **2003**, *9*.
131. Klibi, J.; Niki, T.; Riedel, A.; Pioche-Durieu, C.; Souquere, S.; Rubinstein, E.; Moulec, S. L. E.; Guigay, J.; Hirashima, M.; Guemira, F.; et al. Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells. *Blood* **2009**, *113*.
132. Zhang, H.-G.; Liu, C.; Su, K.; Yu, S.; Zhang, L.; Zhang, S.; Wang, J.; Cao, X.; Grizzle, W.; Kimberly, R. P. A Membrane Form of TNF- α Presented by Exosomes Delays T Cell Activation-Induced Cell Death. *The Journal of Immunology* **2006**, *176*.
133. Papa, A.; Chen, M.; Pandolfi, P. P. Pills of PTEN? in and out for tumor suppression. *Cell Res* **2013**, *23*.
134. Putz, U.; Howitt, J.; Doan, A.; Goh, C. P.; Low, L. H.; Silke, J.; Tan, S. S. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. *Sci Signal* **2012**, *5*.
135. Czystowska, M.; Han, J.; Szczepanski, M. J.; Szajnik, M.; Quadrini, K.; Brandwein, H.; Hadden, J. W.; Signorelli, K.; Whiteside, T. L. IIRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. *Cell Death Differ* **2009**, *16*.
136. Liu, Z. M.; Wang, Y. bin; Yuan, X. H. Exosomes from murine-derived GL26 cells promote glioblastoma tumor growth by reducing number and function of CD8+T cells. *Asian Pacific Journal of Cancer Prevention* **2013**, *14*.
137. Clayton, A.; Mitchell, J. P.; Court, J.; Mason, M. D.; Tabi, Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. *Cancer Res* **2007**, *67*.
138. Szajnik, M.; Czystowska, M.; Szczepanski, M. J.; Mandapathil, M.; Whiteside, T. L. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). *PLoS One* **2010**, *5*.

139. Fleming, V.; Hu, X.; Weber, R.; Nagibin, V.; Groth, C.; Altevogt, P.; Utikal, J.; Umansky, V. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. *Front Immunol* **2018**, *9*.
140. Xiang, X.; Poliakov, A.; Liu, C.; Liu, Y.; Deng, Z. bin; Wang, J.; Cheng, Z.; Shah, S. v.; Wang, G. J.; Zhang, L.; et al. Induction of myeloid-derived suppressor cells by tumor exosomes. *Int J Cancer* **2009**, *124*.
141. Lima, L. G.; Ham, S.; Shin, H.; Chai, E. P. Z.; Lek, E. S. H.; Lobb, R. J.; Müller, A. F.; Mathivanan, S.; Yeo, B.; Choi, Y.; et al. Tumor microenvironmental cytokines bound to cancer exosomes determine uptake by cytokine receptor-expressing cells and biodistribution. *Nat Commun* **2021**, *12*.
142. Oo, M. W.; Kawai, H.; Takabatake, K.; Tomida, S.; Eguchi, T.; Ono, K.; Shan, Q.; Ohara, T.; Yoshida, S.; Omori, H.; et al. Resident stroma-secreted chemokine CCL2 governs myeloid-derived suppressor cells in the tumor microenvironment. *JCI Insight* **2022**, *7*.
143. Lundholm, M.; Schröder, M.; Nagaeva, O.; Baranov, V.; Widmark, A.; Mincheva-Nilsson, L.; Wikström, P. Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: Mechanism of immune evasion. *PLoS One* **2014**, *9*.
144. Jamieson, A. M.; Diefenbach, A.; McMahon, C. W.; Xiong, N.; Carlyle, J. R.; Raulet, D. H. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. *Immunity* **2002**, *17*.
145. Clayton, A.; Mitchell, J. P.; Court, J.; Linnane, S.; Mason, M. D.; Tabi, Z. Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression. *The Journal of Immunology* **2008**, *180*.
146. Szczepanski, M. J.; Szajnlik, M.; Welsh, A.; Whiteside, T. L.; Boyiadzis, M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor- β 1. *Haematologica* **2011**, *96*.
147. Pyfferoen, L.; Brabants, E.; Everaert, C.; de Cabooter, N.; Heyns, K.; Deswarte, K.; Vanheerswyngheles, M.; de Prijck, S.; Waegemans, G.; Dullaers, M.; et al. The transcriptome of lung tumor-infiltrating dendritic cells reveals a tumor-supporting phenotype and a microRNA signature with negative impact on clinical outcome. *Oncoimmunology* **2017**, *6*.
148. Keirsse, J.; van Damme, H.; van Ginderachter, J. A.; Laoui, D. Exploiting tumor-associated dendritic cell heterogeneity for novel cancer therapies. *J Leukoc Biol* **2017**, *102*.
149. Motta, J. M.; Rumjanek, V. M. Sensitivity of dendritic cells to microenvironment signals. *J Immunol Res* **2016**, *2016*.
150. Ning, Y.; Shen, K.; Wu, Q.; Sun, X.; Bai, Y.; Xie, Y.; Pan, J.; Qi, C. Tumor exosomes block dendritic cells maturation to decrease the T cell immune response. *Immunol Lett* **2018**, *199*.
151. Eguchi, T.; Taha, E. A. Extracellular Vesicle-Associated Moonlighting Proteins: Heat Shock Proteins and Metalloproteinases. In; **2020**.
152. Eguchi, T.; Calderwood, S. K.; Takigawa, M.; Kubota, S.; Kozaki, K. I. Intracellular MMP3 Promotes HSP Gene Expression in Collaboration With Chromobox Proteins. *J Cell Biochem* **2017**, *118*.
153. Eguchi, T.; Kubota, S.; Kawata, K.; Mukudai, Y.; Uehara, J.; Ohgawara, T.; Ibaragi, S.; Sasaki, A.; Kuboki, T.; Takigawa, M. Novel transcriptional regulation of CCN2/CTGF by nuclear translocation of MMP3. In *CCN Proteins in Health and Disease: An Overview of the Fifth International Workshop on the CCN Family of Genes*; **2010**.
154. Eguchi, T.; Kubota, S.; Kawata, K.; Mukudai, Y.; Uehara, J.; Ohgawara, T.; Ibaragi, S.; Sasaki, A.; Kuboki, T.; Takigawa, M. Novel Transcription Factor-Like Function of Human Matrix Metalloproteinase 3 Regulating the CTGF/CCN2 Gene. *Mol Cell Biol* **2008**, *28*, 2391.
155. Zhang, Q.; Higginbotham, J. N.; Jeppesen, D. K.; Yang, Y. P.; Li, W.; McKinley, E. T.; Graves-Deal, R.; Ping, J.; Britain, C. M.; Dorsett, K. A.; et al. Transfer of Functional Cargo in Exomeres. *Cell Rep* **2019**, *27*, 940-954.e6.
156. Dall'Olio, F.; Chiricolo, M.; Mariani, E.; Facchini, A. Biosynthesis of the cancer-related sialyl- α 2,6-lactosaminyl epitope in colon cancer cell lines expressing beta-galactoside α 2,6-sialyltransferase under a constitutive promoter. *Eur J Biochem* **2001**, *268*, 5876-5884.
157. Schultz, M. J.; Holdbrooks, A. T.; Chakraborty, A.; Grizzle, W. E.; Landen, C. N.; Buchsbaum, D. J.; Conner, M. G.; Arend, R. C.; Yoon, K. J.; Klug, C. A.; et al. The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. *Cancer Res* **2016**, *76*, 3978-3988.
158. Eguchi, T.; Ono, K.; Kawata, K.; Okamoto, K.; Calderwood, S. K. Regulatory Roles of HSP90-Rich Extracellular Vesicles. In; **2019**.
159. Eguchi, T.; Prince, T. L.; Tran, M. T.; Sogawa, C.; Lang, B. J.; Calderwood, S. K. MZF1 and SCAND1 reciprocally regulate CDC37 Gene expression in prostate cancer. *Cancers (Basel)* **2019**, *11*.
160. Taha, E. A.; Ono, K.; Eguchi, T. Roles of extracellular HSPs as biomarkers in immune surveillance and immune evasion. *Int J Mol Sci* **2019**, *20*.
161. Calderwood, S. K.; Gong, J.; Murshid, A. Extracellular HSPs: The complicated roles of extracellular HSPs in immunity. *Front Immunol* **2016**, *7*.
162. Dijkstra, S.; Birker, I. L.; Smit, F. P.; Leyten, G. H. J. M.; de Reijke, T. M.; van Oort, I. M.; Mulders, P. F. A.; Jannink, S. A.; Schalken, J. A. Prostate cancer biomarker profiles in urinary sediments and exosomes. *J Urol* **2014**, *191*, 1132-1138.

163. 163. Aushev, V. N.; Zborovskaya, I. B.; Laktionov, K. K.; Girard, N.; Cros, M. P.; Herceg, Z.; Krutovskikh, V. Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma. *PLoS One* **2013**, *8*.
164. 164. Keller, S.; Ridinger, J.; Rupp, A. K.; Janssen, J. W. G.; Altevogt, P. Body fluid derived exosomes as a novel template for clinical diagnostics. *J Transl Med* **2011**, *9*.
165. 165. Kim, J.; Shim, J. S.; Han, B. H.; Kim, H. J.; Park, J.; Cho, I. J.; Kang, S. G.; Kang, J. Y.; Bong, K. W.; Choi, N. Hydrogel-based hybridization chain reaction (HCR) for detection of urinary exosomal miRNAs as a diagnostic tool of prostate cancer. *Biosens Bioelectron* **2021**, *192*.
166. 166. Ahadi, A.; Khoury, S.; Losseva, M.; Tran, N. A comparative analysis of lncRNAs in prostate cancer exosomes and their parental cell lines. *Genom Data* **2016**, *9*, 7–9.
167. 167. Vardaki, I.; Ceder, S.; Rutishauser, D.; Baltatzis, G.; Foukakis, T.; Panaretakis, T. Periostin is identified as a putative metastatic marker in breast cancer-derived exosomes. *Oncotarget* **2016**, *7*, 74966–74978.
168. 168. Herreros-Villanueva, M.; Bujanda, L. Glypican-1 in exosomes as biomarker for early detection of pancreatic cancer. *Ann Transl Med* **2016**, *4*.
169. 169. Taylor, D. D.; Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. *Gynecol Oncol* **2008**, *110*, 13–21.
170. 170. Looze, C.; Yui, D.; Leung, L.; Ingham, M.; Kaler, M.; Yao, X.; Wu, W. W.; Shen, R. F.; Daniels, M. P.; Levine, S. J. Proteomic Profiling of Human Plasma Exosomes Identifies PPAR γ as an Exosome-associated Protein. *Biochem Biophys Res Commun* **2009**, *378*, 433.
171. 171. Machida, T.; Tomofuji, T.; Maruyama, T.; Yoneda, T.; Ekuni, D.; Azuma, T.; Miyai, H.; Mizuno, H.; Kato, H.; Tsutsumi, K.; et al. miR-1246 and miR-4644 in salivary exosome as potential biomarkers for pancreatobiliary tract cancer. *Oncol Rep* **2016**, *36*, 2375–2381.
172. 172. Théry, C.; Witwer, K. W.; Aikawa, E.; Alcaraz, M. J.; Anderson, J. D.; Andriantsitohaina, R.; Antoniou, A.; Arab, T.; Archer, F.; Atkin-Smith, G. K.; et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. *J Extracell Vesicles* **2018**, *7*.
173. 173. Kang, M.; Jordan, V.; Blenkiron, C.; Chamley, L. W. Biodistribution of extracellular vesicles following administration into animals: A systematic review. *J Extracell Vesicles* **2021**, *10*.
174. 174. Vader, P.; Mol, E. A.; Pasterkamp, G.; Schiffelers, R. M. Extracellular vesicles for drug delivery. *Adv Drug Deliv Rev* **2016**, *106*, 148–156.
175. 175. van der Meel, R.; Fens, M. H. A. M.; Vader, P.; van Solinge, W. W.; Eniola-Adefeso, O.; Schiffelers, R. M. Extracellular vesicles as drug delivery systems: lessons from the liposome field. *J Control Release* **2014**, *195*, 72–85.
176. 176. Terstappen, G. C.; Meyer, A. H.; Bell, R. D.; Zhang, W. Strategies for delivering therapeutics across the blood-brain barrier. *Nat Rev Drug Discov* **2021**, *20*, 362–383.
177. 177. Nikfarjam, S.; Rezaie, J.; Zolbanin, N. M.; Jafari, R. Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine. *Journal of Translational Medicine* **2020** *18:1* **2020**, *18*, 1–21.
178. 178. Murphy, D. E.; de Jong, O. G.; Brouwer, M.; Wood, M. J.; Lavieu, G.; Schiffelers, R. M.; Vader, P. Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. *Experimental & Molecular Medicine* **2019** *51:3* **2019**, *51*, 1–12.
179. 179. Hoshino, A.; Costa-Silva, B.; Shen, T. L.; Rodrigues, G.; Hashimoto, A.; Tesic Mark, M.; Molina, H.; Kohsaka, S.; di Giannatale, A.; Ceder, S.; et al. Tumour exosome integrins determine organotropic metastasis. *Nature* **2015** *527:7578* **2015**, *527*, 329–335.
180. 180. Mu, W.; Provaznik, J.; Hackert, T.; Zöller, M. Tspan8-Tumor Extracellular Vesicle-Induced Endothelial Cell and Fibroblast Remodeling Relies on the Target Cell-Selective Response. *Cells* **2020**, *9*.
181. 181. Matsumoto, A.; Takahashi, Y.; Nishikawa, M.; Sano, K.; Morishita, M.; Charoenviriyakul, C.; Saji, H.; Takakura, Y. Role of Phosphatidylserine-Derived Negative Surface Charges in the Recognition and Uptake of Intravenously Injected B16BL6-Derived Exosomes by Macrophages. *J Pharm Sci* **2017**, *106*, 168–175.
182. 182. Soekmadji, C.; Li, B.; Huang, Y.; Wang, H.; An, T.; Liu, C.; Pan, W.; Chen, J.; Cheung, L.; Falcon-Perez, J. M.; et al. The future of Extracellular Vesicles as Theranostics - an ISEV meeting report. *J Extracell Vesicles* **2020**, *9*.
183. 183. Yang, M.; Wu, S. Y. The Advances and Challenges in Utilizing Exosomes for Delivering Cancer Therapeutics. *Front Pharmacol* **2018**, *9*, 735.
184. 184. Rezabakhsh, A.; Sokullu, E.; Rahbarghazi, R. Applications, challenges and prospects of mesenchymal stem cell exosomes in regenerative medicine. *Stem Cell Res Ther* **2021**, *12*.
- 185.